Forwarders face profitability test as freight markets look set to stabilise
As global freight markets begin to show signs of stabilisation after months of disruption, the industry’s largest forwarders have shown ...
Since the credit crunch over a decade ago and one patent cliff after another*, US drug maker behemoth Pfizer has gone through its pipeline troubles seriously challenged, yet has emerged mostly unscathed.
And now, with the Covid-19 vaccine goldmine in sight**, the future may have a completely different taste if a) its magic dose receives the final, green light from the regulators and, equally important b) it gets the logistics angle of its business proposition right.
(*A bit of background is here: 2012, 2014, 2016, ...
Comment on this article